In vitro proliferation of normal and leukaemic human leukocytes controlled by an inhibitory endopeptide.
GI-3, an endogenous inhibitory fraction isolated from leukocytes, selectively inhibits the proliferation of granuloid precursor cells in a non-toxic manner. Its active principle was determined as an acidic chlor-tolidine positive decapeptide [ 3 ]. The in vitro effect on normal and acute leukaemic human bone marrow and blood cells was examined. A dose dependent inhibition by GI-3 of 3H-TdR incorporation into myeloid cells of normal bone marrow was found, the sensitivity of human cells being higher than that of rat cells. The proliferation of the target leukaemic bone marrow and blood cells (AML, AMMoL) was also decreased by the endogenous inhibitor in a dose dependent manner in untreated subjects as well as in patients in remission or relapse. The rate of inhibition of leukaemic of well-known cytostatics (adriamycin hydrochloride, dianhydrogalactitol) applied for comparison. Beyond its direct cytostatic effect, GI-3 could be used in the differential diagnosis of blastic leukaemias, complementing the routine cytochemical methods.
D000328:Adult; D000368:Aged; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects*; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D003864:Depression, Chemical; D003961:Dianhydrogalactitol / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D005260:Female; D006801:Humans; D007938:Leukemia / Q000473:pathology*; D007945:Leukemia, Lymphoid / Q000473:pathology; D007951:Leukemia, Myeloid / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000473:pathology; D007962:Leukocytes / Q000166:cytology / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000494:pharmacology*; D051381:Rats
D010455:Peptides; D003961:Dianhydrogalactitol; D004317:Doxorubicin